Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Melanoma

Interventions

DRUG

Glycoprotein 100 (GP100): 209-217 (210M)

DRUG

Interleukin-2 (IL-2)

720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).

DRUG

Montanide ISA 51

DRUG

Melanoma antigen recognized by T-cells (MART)-1: 27-35

DRUG

27-35 (27L): melanoma antigen recognized by T-cells (MART)-1

DRUG

melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)

Trial Locations (1)

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00059475 - Peptide Vaccination for Patients at High Risk for Recurrent Melanoma | Biotech Hunter | Biotech Hunter